

# Mitochondrial Dysfunction in Acute and Chronic Neurodegeneration

## Guest Editor



**Dr. Giacomo Lazzarino**

UniCamillus - Saint Camillus International University of Health and Medical Sciences, Rome, Italy

[giacomo.lazzarino@unicamillus.org](mailto:giacomo.lazzarino@unicamillus.org)



**Dr. Nunzio Vicario**

Department of Biomedical and Biotechnological Sciences, University of Catania, Italy

[nunziovicario@unict.it](mailto:nunziovicario@unict.it)

## Message from the Guest Editor

Dear Colleagues,

A Pubmed search for “Mitochondrial dysfunction + neurodegeneration” conducted on January 14, 2022, revealed that 1,809 full-length papers had been published up to this date. This highlights the central role of mitochondria in the pathobiological mechanisms of development and progression of acute (stroke, traumatic brain injury) and chronic (amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, etc.) neurodegeneration. A better understanding of the biochemical/metabolic/molecular processes involving mitochondrial malfunction in acute and chronic neurodegeneration may allow the development of new and more effective pharmacological treatments.

The goal of this special issue is to present new advances that connect alterations in mitochondrial function with the onset and/or progression of acute and chronic neurodegeneration. These new findings can be obtained from either experimental cellular/animal models or from clinical studies. Papers reporting the results of new drug treatments that target mitochondria are most welcome. Reviews highlighting the most recent information on specific acute or chronic neurodegenerative diseases will also be considered.

Dr. Giacomo Lazzarino and Dr. Nunzio Vicario

*Guest Editors*

Submission Deadline: **31 December 2022**

Submission: <https://www.imrpress.com/journal/FBL>

Science Citation Index Expanded: **4.009** (2020)

Contact us: [FBL@imrpress.com](mailto:FBL@imrpress.com)